Nalu Bio is a San Francisco-based female-founded and led biotech company established in 2019. It specializes in developing no-high, chemistry-derived cannabinoids to address global health and wellness challenges like pain, anxiety, sleep, and weight management. The company's proprietary platform produces ultra-pure minor cannabinoids like CBD, THCV, CBN, CBC, and CBG through organic chemistry. These cannabinoids maintain the plant's molecular identity while addressing drawbacks like safety, predictability, scalability, and sustainability issues. Nalu Bio offers standalone cannabinoid ingredients and AI-driven combinations with bioactives, providing effective, safe, and consistent products for food, beverage, health, wellness, personal care, and therapeutics. In February 2024, Nalu Bio partnered with AI leader PIPA to create novel cannabinoid-bioactive combinations backed by science and data. In February 2023, the company raised a USD 12 million Series A funding led by Intrinsic Capital Partners.
Key customers and partnerships
In February 2024, Nalu Bio announced a first-of-its-kind partnership with PIPA, an AI leader in nutrition, health, and wellness innovation. This collaboration aims to leverage predictive AI modeling to identify optimal combinations of Nalu Bio's cannabinoids with unique bioactives like vitamins, protein, fiber, antioxidants, probiotics, and superfoods for global consumer packaged goods (CPG) companies.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.